Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Pharmacotherapy ; 29(3): 347-51, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19249952

RESUMO

Antibiotic treatment for pelvic inflammatory disease (PID) is often broad spectrum and targets a diverse range of vaginal flora. Treatment of PID in nursing mothers presents a particular clinical challenge because use of antimicrobials during breastfeeding poses several potential risks to infants. Excretion of drugs into breast milk can occur through different mechanisms and depends on the characteristics of both the drug and the mother. Whether daptomycin is excreted into breast milk is unknown, as is its subsequent exposure to breastfeeding infants and the associated risks. We describe a case of PID caused by methicillin-resistant Staphylococcus aureus, an uncommon pathogen in PID, in a breastfeeding mother who was successfully treated with daptomycin. Daptomycin concentrations in her breast milk were measured to determine potential exposure to her infant. These concentrations were extremely low, with an estimated milk:plasma ratio of 0.0012. Although additional confirmatory studies are needed, daptomycin may be a reasonable option in the treatment of PID caused by gram-positive organisms that are resistant to other antibiotics.


Assuntos
Antibacterianos/metabolismo , Daptomicina/metabolismo , Staphylococcus aureus Resistente à Meticilina , Leite Humano/metabolismo , Doença Inflamatória Pélvica/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Adulto , Antibacterianos/uso terapêutico , Aleitamento Materno , Daptomicina/uso terapêutico , Feminino , Humanos , Lactente , Doença Inflamatória Pélvica/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA